5-HT5A Receptor Mechanistic Studies with SB-699551

The contract focuses on investigating the mechanistic role of the 5-HT5A receptor in mediating the effects of psychoactive drugs through co-treatment with SB-699551, a selective antagonist. The work entails conducting dose-response studies to determine how varying concentrations of SB-699551 modulate drug-induced behaviors and physiological responses, with an emphasis on establishing clear pharmacodynamic relationships. Functional assays will be integrated with transcriptomic analyses to identify downstream molecular pathways and gene expression changes triggered by receptor modulation, enabling a systems-level understanding of how 5-HT5A influences drug action. This subcontract, issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, is classified under NAICS code 541715 for research and development in the life sciences. The project requires detailed experimental planning and data integration across multiple biological domains, demanding expertise in neuropharmacology, molecular biology, and bioinformatics. Proposals must be submitted by July 6, 2026, with the work expected to be performed at the contractor’s facility, though no specific location is mandated. The goal is to generate robust mechanistic insights that could inform future therapeutic strategies targeting the 5-HT5A receptor in drug development and behavioral pharmacology.